Dahlia Ismail
About
In The Last Decade
Dahlia Ismail
20 papers receiving 567 citations
Peers
Comparison fields: 5 of 38
- Public Health, Environmental and Occupational Health 551
- Ophthalmology 259
- Radiology, Nuclear Medicine and Imaging 223
- Pharmaceutical Science 178
- Immunology and Allergy 148
Countries citing papers authored by Dahlia Ismail
This map shows the geographic impact of Dahlia Ismail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dahlia Ismail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dahlia Ismail more than expected).
Fields of papers citing papers by Dahlia Ismail
This network shows the impact of papers produced by Dahlia Ismail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dahlia Ismail. The network helps show where Dahlia Ismail may publish in the future.
Co-authorship network of co-authors of Dahlia Ismail
This figure shows the co-authorship network connecting the top 25 collaborators of Dahlia Ismail. A scholar is included among the top collaborators of Dahlia Ismail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dahlia Ismail. Dahlia Ismail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 7 | |
| 5 | 28 | |
| 6 | Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials | 1 |
| 7 | 27 | |
| 8 | 39 | |
| 9 | 73 | |
| 10 | 17 | |
| 11 | 18 | |
| 12 | Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study | 1 |
| 13 | 37 | |
| 14 | 68 | |
| 15 | Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED) | 1 |
| 16 | 31 | |
| 17 | Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: Experience through the French early access program | 2 |
| 18 | The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion | 1 |
| 19 | The Effect of Cyclokat® (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial | 1 |
| 20 | Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.